

# CITATION REPORT

List of articles citing

## Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

DOI: 10.1007/s13300-017-0254-7  
Diabetes Therapy, 2017, 8, 365-376.

**Source:** <https://exaly.com/paper-pdf/66701916/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
41	SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study. <i>Journal of Diabetes and Metabolic Disorders</i> , <b>2017</b> , 16, 27	2.5	12
40	Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center. <i>Diabetology and Metabolic Syndrome</i> , <b>2017</b> , 9, 96	5.6	11
39	What have we learnt from "real world" data, observational studies and meta-analyses. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20 Suppl 1, 47-58	6.7	32
38	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2018</b> , 34, e2981	7.5	12
37	Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1397-1402	3.6	3
36	Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. <i>Circulation Research</i> , <b>2018</b> , 122, 1439-1459	15.7	148
35	How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 1163-1170	3.6	1
34	Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1661-1667	6.7	14
33	Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study. <i>BMJ Open Diabetes Research and Care</i> , <b>2019</b> , 7, e000627	4.5	10
32	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 1-13	3.6	12
31	Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. <i>Clinical Diabetes</i> , <b>2019</b> , 37, 316-337	2.9	5
30	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , <b>2019</b> , 40, 2907-2919	9.5	22
29	Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey. <i>Diabetes and Vascular Disease Research</i> , <b>2020</b> , 17, 1479164120945674	3.3	0
28	Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment. <i>Diabetes</i> , <b>2020</b> , 69, 2075-2085	0.9	14
27	Real-World Clinical Experience with SGLT2 Inhibitors: Use of Special Screening Tool for Type 2 Diabetes Patients to Avoid Serious Adverse Events: A Single-Centre Prospective Study. <i>Dubai Diabetes and Endocrinology Journal</i> , <b>2020</b> , 26, 38-43	1.4	0
26	Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care. <i>Diabetic Medicine</i> , <b>2020</b> , 37, 1499-1508	3.5	3
25	Impact on guidelines: The general practitioner point of view. <i>Diabetes Research and Clinical Practice</i> , <b>2020</b> , 166, 108091	7.4	3

24	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. <i>Primary Care Diabetes</i> , <b>2021</b> , 15, 31-51	2.4	13
23	How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 838-843	6.7	3
22	Trends in Factors Affecting Pregnancy Outcomes Among Women With Type 1 or Type 2 Diabetes of Childbearing Age (2004-2017). <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 596633	5.7	2
21	Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital. <i>Chinese Medical Journal</i> , <b>2021</b> , 134, 1317-1323	2.9	13
20	Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study. <i>Revista Clínica Espanola</i> , <b>2021</b> , 221, 517-528	0.5	
19	Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. <i>BMC Nephrology</i> , <b>2021</b> , 22, 177	2.7	2
18	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 159	8.7	3
17	Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study. <i>BMJ Open</i> , <b>2021</b> , 11, e046912	3	0
16	Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. <i>Endocrine and Metabolic Science</i> , <b>2021</b> , 4, 100102	1	
15	Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 33-48	3.6	10
14	Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study. <i>Revista Clínica Espanola</i> , <b>2020</b> , 221, 517-517	0.7	2
13	Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data. <i>Journal of Clinical Medicine Research</i> , <b>2017</b> , 9, 605-612	2.9	13
12	Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective Real-world Setting Study. <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2019</b> , 23, 50-55	1.7	3
11	Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose-lowering efficacy: cohort study using trial and routine clinical data.		1
10	Predicting real-world hypoglycemia risk in American adults with type 1 or 2 diabetes mellitus prescribed insulin and/or secretagogues: Protocol for a prospective, 12-wave internet-based panel survey with email support (the iNPHORM study, USA).. <i>JMIR Research Protocols</i> , <b>2022</b> ,	2	0
9	A Comparison of Individuals with Diabetes and EMPA-REG Trial Participants: Exploring Aspects of External Validity.. <i>Journal of General Internal Medicine</i> , <b>2022</b> , 1	4	
8	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.. <i>Primary Care Diabetes</i> , <b>2022</b> ,	2.4	0
7	Predicting Real-world Hypoglycemia Risk in American Adults With Type 1 or 2 Diabetes Mellitus Prescribed Insulin and/or Secretagogues: Protocol for a Prospective, 12-Wave Internet-Based Panel Survey With Email Support (the iNPHORM [Investigating Novel Predictions of Hypoglycemia Occurrence Using Real-world Models] Study) (Preprint)		

- 6 Is HbA1c a valid surrogate for mortality in type 2 diabetes? Evidence from a meta-analysis of randomized trials.. *Acta Diabetologica*, **2022**, 3.9
- 5 Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study. 9, ○
- 4 Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol. **2022**, 12, e066491 ○
- 3 Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. **2022**, 4, e873-e883 ○
- 2 Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy. **2023**, 3, 329-363 ○
- 1 Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study. **2023**, Publish Ahead of Print, ○